Get the latest Science News and Discoveries
Insilico Medicine receives NMPA IND clearance for innovative oral candidate ISM8969/HT-001, the brain-penetrant NLRP3 inhibitor co-developed with Hygtia Therapeutics - EurekAlert!
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
None
Or read this on Eureka Alert